{"schema_version":"secwatch.filing_event.v1","accession":"0001339970-26-000030","form_type":"8-K","ticker":"ATYR","cik":"0001339970","company_name":"aTYR PHARMA INC","filed_at":"2026-05-15T12:02:37+00:00","discovered_at":"2026-05-15T12:05:00.218088+00:00","generated_at":"2026-05-15T12:06:03.580960+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"aTyr Pharma reports $68.3M cash; plans Phase 3 for efzofitimod after FDA meeting","bullets":["Cash, cash equivalents, restricted cash and investments: $68.3M as of March 31, 2026.","Plans to file IND in June 2026 for a Phase 3 study of efzofitimod in pulmonary sarcoidosis with restrictive lung disease; primary endpoint FVC at week 48.","Phase 3 study to enroll ~372 patients; randomized, double-blind, placebo-controlled, 54 weeks.","On track to complete enrollment in Phase 2 EFZO-CONNECT study for SSc-ILD in first half 2026.","R&D expenses $7.3M and G&A expenses $4.1M for Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001339970-26-000030","json":"https://secwatch.observer/filing/0001339970-26-000030.json","markdown":"https://secwatch.observer/filing/0001339970-26-000030.md","text":"https://secwatch.observer/filing/0001339970-26-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339970/000133997026000030/0001339970-26-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339970/000133997026000030/atyr-20260515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T12:06:03.580960+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"aac3225c67c3b134ad0e5c5ce890fd90a53a05c9","claim":"aTYR PHARMA INC reported financial results for the quarter ended March 31, 2026.","evidence_excerpt":"On May 15, 2026, aTyr Pharma, Inc. issued a press release announcing financial results for the quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1339970/000133997026000030/0001339970-26-000030-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}